Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of niraparib plus anlotinib in recurrent or metastatic endometrial cancer
ChiCTR2000035853Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib and anlotinib in endometrial cancer (EC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: objective response rate. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
niraparibanlotinib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR2000035853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035853.